Posttransplantationsdiabetes mellitus

Association AD (2019) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes – 2019. Diabetes Care 42:13–S28

Sharif A, Hecking M, de Vries APJ et al (2014) Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant 14:1992–2000

Petersmann A, Müller-Wieland D, Müller UA et al (2019) Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetol Stoffwechs 14:S111–S118

Langsford D, Dwyer K (2015) Dysglycemia after renal transplantation: definition, pathogenesis, outcomes and implications for management. World J Diabetes 6:1132–1151

Bergrem HA, Valderhaug TG, Hartmann A et al (2010) Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol 5:616–622

Koppe L, Pelletier CC, Alix PM et al (2014) Insulin resistance in chronic kidney disease: new lessons from experimental models. Nephrol Dial Transplant 29:1666–1674

Shimada H, Uchida J, Nishide S et al (2019) Comparison of glucose tolerance between kidney transplant recipients and healthy controls. J Clin Med. https://doi.org/10.3390/jcm8070920

Chang S, Jiang J (2018) Association of body mass index and the risk of new-onset diabetes after kidney transplantation: a meta-analysis. Transplant Proc 50:1316–1325

Kim Y, Jung AD, Dhar VK et al (2018) Laparoscopic sleeve gastrectomy improves renal transplant candidacy and posttransplant outcomes in morbidly obese patients. Am J Transplant 18:410–416

Garnier A‑S, Duveau A, Planchais M et al (2018) Serum magnesium after kidney transplantation: a systematic review. Nutrients 10:729

Heit JJ, Apelqvist AA, Gu X et al (2006) Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 443:345–349

Webster A, Woodroffe RC, Taylor RS et al (2005) Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003961.pub2

Vincenti F, Friman S, Scheuermann E et al (2007) Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7:1506–1514

Chan L, Andres A, Bunnapradist S et al (2012) Renal function and NODM in de novo renal transplant recipients treated with standard and reduced levels of tacrolimus in combination with EC-MPS. J Transplant 2012:941640

Pascual J, Galeano C, Royuela A, Zamora J (2010) A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 90:343–349

Tillmann FP, Schmitz M, Rump LC, Quack I (2018) Impact of low-dose steroids on HbA1c levels and development of pre-diabetes and NODAT in non-diabetic renal transplant recipients on long-term follow-up. Int Urol Nephrol 50:771–777

Gyurus E, Kaposztas Z, Kahan BD (2011) Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc 43:1583–1592

Sommerer C, Witzke O, Lehner F et al (2018) Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrol 19:237

Baid-Agrawal S, Frei U, Reinke P et al (2009) Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients. Am J Transplant 9:2777–2784

Hjelmesaeth J, Sagedal S, Hartmann A et al (2004) Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 47:1550–1556

Delgado P, Diaz JM, Silva I et al (2008) Unmasking glucose metabolism alterations in stable renal transplant recipients: a multicenter study. Clin J Am Soc Nephrol 3:808–813

Aouad LJ, Clayton P, Wyburn KR et al (2018) Evolution of Glycemic control and variability after kidney transplant. Transplantation 102:1563–1568

Valderhaug TG, Hjelmesæth J, Hartmann A et al (2011) The association of early post-transplant glucose levels with long-term mortality. Diabetologia 54:1341–1349

Hjelmesaeth J, Hartmann A, Leivestad T et al (2006) The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 69:588–595

Cole EH, Johnston O, Rose CL, Gill JS (2008) Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 3:814–821

Eide IA, Halden TAS, Hartmann A et al (2017) Associations between posttransplantation diabetes mellitus and renal graft survival. Transplantation 101:1282–1289

Vanrenterghem Y, Bresnahan B, Campistol J et al (2011) Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 91:976–983

Schiffer L, Krautzig S, Gerbig D et al (2016) Rehabilitation after kidney transplantation: old problems and new structures. Internist 57:49–53

Kuningas K, Driscoll J, Mair R et al (2019) Comparing glycaemic benefits of active versus passive lifestyle intervention in kidney allograft recipients (CAVIAR): a randomised controlled trial. Transplantation. https://doi.org/10.1097/TP.0000000000002969

Gomes-Neto AW, Osté MCJ, Sotomayor CG et al (2019) Fruit and vegetable intake and risk of posttransplantation diabetes in renal transplant recipients. Diabetes Care 42:1645–1652

Sharif A, Moore R, Baboolal K (2008) Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 85:353–358

Hecking M, Haidinger M, Döller D et al (2012) Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 23:739–749

Strøm Halden TA, Åsberg A, Vik K et al (2014) Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant 29:926–933

Kurian B, Joshi R, Helmuth A (2008) Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract 14:979–984

Zhu J, Yu X, Zheng Y et al (2020) Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. Lancet Diabetes Endocrinol 8:192–205

Mahling M, Schork A, Nadalin S et al (2019) Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 44:984–992

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128

Liou J‑H, Liu Y‑M, Chen C‑H (2018) Management of diabetes mellitus with glucagonlike peptide‑1 agonist Liraglutide in renal transplant recipients: a retrospective study. Transplant Proc 50:2502–2505